PCN210 Long-Term Eq-5d Score For Patients With Metastatic Breast Cancer; Comparison Of First-Line Oral S-1 And Taxane Therapies In The Randomized “Select” Trial  by Fukuda, T et al.
 VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 3 3 5 – A 7 6 6  A467
mean estimates in QALYs in favour of vinflumine can be quite different depending 
on how censored patients are handled especially when proportion of censoring 
differs by treatment group.
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Objectives: The present study used long-term EQ-5D scores to evaluate patients 
with metastatic breast cancer (MBC) in a randomized control trial (RCT). MethOds: 
Patients with HER2-negative MBC were randomly allocated to the S-1 (an oral fluo-
ropyrimidine) or taxane (paclitaxel or docetaxel) group. The primary endpoint was 
overall survival (OS), and QOL was a secondary endpoint. EQ-5D scores were sur-
veyed at pre-treatment, three months after randomization, and every six months 
thereafter. Mean scores were assessed by repeated measured ANOVA including 
baseline, group, time and interaction of group and time. Minimal important dif-
ference (MID) analysis was also performed by defining the MID of EQ-5D as 0.05 
or 0.1. When MID analysis was applied to the score during fist-line therapy, pro-
gression was treated as a competing risk. Results: A total of 618 patients with 
MBC were randomly allocated to both groups (N= 309 each). S-1 was non-inferior to 
taxanes for OS (median OS: S-1, 35.0 months; taxanes, 37.2 months). The number 
of patients in the EQ-5D population was 208 and 175 in S-1 and taxane groups, 
respectively. Mean duration of the EQ-5D response was 21 months for both groups. 
Mean EQ-5D scores up to 60 months were 0.748 and 0.741 in S1 and taxane groups, 
respectively. No significant difference was observed by ANOVA or MID analysis. 
During first-line therapy, mean EQ-5D score was 0.810 and 0.781 in S-1 and taxane 
groups up to 36 months, although in the post-progression period, scores decreased 
to 0.729 and 0.703, respectively. Gray’s test revealed that S-1 significantly delayed 
the decrease in QOL score. The size of the MID (0.05 or 0.1) did not influence the 
results. cOnclusiOns: This study analyzed long-term EQ-5D scores of patients 
with MBC from RCT data. The QOL score of S-1 was higher during first-line therapy.
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Objectives: Discrete choice experiments (DCE) are an important method for 
capturing data on the patient preferences. Neuroendocrine tumors (NET) are a rare 
disease and therefore a sufficient number of study participants for preference 
studies is difficult to recruit. Moreover there is hardly any international stand-
ard for the determination of the appropriate number of study participants in 
DCEs. Amongst others, suggestions on sample size have been made by Orme 
and Louviere. MethOds: Patient-relevant outcomes concerning alternative 
treatment options of NET were weighted using a DCE including six attributes. 
Akaike information criterion (AIC), and Bayesian information criterion (BIC) 
together with the standard error (SE) were used to check the model fit and to 
determine the most appropriate sample size. For the sensitivity analysis dif-
ferent participants were randomly drawn from the study sample. Results: 
N= 275 NET-patients (48.5% male, mean age 58.4 years) could be included. With 
the maximum number of included participants all six attributes resulted in sig-
nificant values (p< 0.05). This sample sizes then accounts for an AIC= 3901.391, 
BIC= 4043.999 and a mean standard error (SE) of 0.057. Within the analysis an 
increasing sample size linearly improves the model fit. When including N= 30 
the mean SE does not fit the given 0.05 level (0.173). This improves with a higher 
sample size. Consequently, including N= 90 results in a mean SE below 0.1 with 
BIC= 4043.999 and AIC= 3901.391. The mean SE falls to 0.065 when including N= 210 
(BIC= 3169.285; AIC= 3032.256) cOnclusiOns: Using the sensitivity analysis it can 
be shown that the model fit improves proportionally. An optimal sample size could 
therefore be approximated. Based on the preliminary results it is evident that with 
the given design and the given number of attributes and level a total N of at least 
275 participants is appropriate to conduct a DCE.
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Objectives: Neuroendocrine tumors (NET) are relatively rare, usually slow-growing 
malignant tumors. So far there are no data on the patient preferences regarding the 
therapy of NET. This empirical study aimed at the elicitation of patient preferences 
in the drug treatment of NET. MethOds: Based on qualitative patient interviews 
and an AHP, patient-relevant outcomes were analyzed and weighted using a discrete 
choice experiment (DCE). Six patient-relevant attributes were included. Patients 
were recruited with the help of a NET support group. For the DCE an experimental 
design (3*3 + 3*6 Design) was created using Ngene. The selected design consisted of 
84 choices, which were divided into 7 blocks. Participants were randomly assigned to 
these blocks. The analysis of DCE included random parameter logit models, condi-
tional logit models, and latent class models. Results: N = 275 NET-patients (51.6% 
female, mean age 58.4 years) participated. Under the chosen decision model the 
preference analysis within the random parameter logit model, taking into account 
Guidelines. Mode equivalence between paper and electronic versions of the EORTC 
Quality of Life Questionnaire (EORTC QLQ-C30;v3.0) and its Breast Cancer Module 
(QLQ-BR23;v1.0) was evaluated, as well as their usability on two electronic devices 
with different screen sizes. MethOds: Adult women with metastatic breast cancer 
(mBC) who had not received chemotherapy for metastatic disease were screened. 
Using an alternating crossover study design, half completed questionnaires on paper 
first, followed by a tablet (10.1″screen) and a handheld (4.5″screen); the other half 
used the handheld first, followed by tablet and paper. To optimize recall, the think-
aloud method was used and cognitive debriefing interviews were conducted after 
each questionnaire was completed on each device. Usability questions were asked 
after completion of both questionnaires on a device. Results: 10 mBC patients 
were interviewed. Most patients reported that their answers would not differ on 
paper vs devices (tablet:C30= 70%;BR23= 100%), (handheld:C30= 90%;BR23= 90%). 
No participants attributed potential differences to interpreting items differently 
on the different modalities. 100% easily accessed questionnaires on the devices, 
understood instructions and easily moved from question-to-question. 90% were 
satisfied with the touchscreens, and all noted they could use either device inde-
pendently. Patients preferred the tablet vs handheld due to its larger screen; yet 
all preferred the handheld’s one-question-per-screen presentation, which allowed 
for greater focus. All patients indicated that screen size did not influence usability 
and that either device was acceptable to complete questionnaires. cOnclusiOns: 
This study demonstrated mode equivalence between paper and electronic versions 
of EORTC-C30 and BR23, as well as between two devices. The devices were equally 
acceptable, providing evidence for their usability to collect PRO information from 
similar patients in clinical trials.
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Objectives: Nonadherence to hormonal therapy is known to impact health out-
comes in patients with breast cancer. We measured nonadherence to aromatase 
inhibitors using a novel, clinic-based patient-reporting system. MethOds: Patients 
of The West Cancer Center (Memphis, TN) were surveyed in the clinic prior to a 
scheduled appointment using the Patient Care Monitor system, a tablet-based, 
patient-reported outcomes platform. Adults diagnosed with breast cancer and 
prescribed an aromatase inhibitor were eligible to participate. The survey included 
30 questions and used three established instruments, including the Morisky 
Medication Adherence Scale and Medication Adherence Reasons Scale. The survey 
polled patients on their adherence to aromatase inhibitors, reasons for nonadher-
ence, and health literacy. Results: Over the course of 45 days, 3016 patients were 
self-screened for eligibility and interest; 1105 indicated interest; and 110 patients 
were fully eligible and completed the survey. Respondents were well-distributed 
by medication: anastrazole (42.2%), exemestane (33.9%), and letrozole (23.9%). 
Most patients (82.6%) reported being fully adherent (missed 0 days) in the past 
week; however, only 67.9% reported high adherence (score = 4) according to the 
Morisky Medication Adherence Scale (Spearman rho= -0.457, p-value< 0.0001). 
Mean adherence values or days missed did not differ significantly by medication 
or health literacy level. Among patients who reported missing at least one day in 
the previous week, the most often cited reasons were: simply missing the dose 
(44.4%), having problems forgetting things (38.9%), and concerns about side effects 
(33.3%). cOnclusiOns: Adherence to hormonal therapy remains suboptimal and 
determining reasons for nonadherence prior to scheduled visits may assist provid-
ers in guiding patients. Moreover, the clinic’s Patient Care Monitor system is a novel 
patient engagement platform to collect patient-reported adherence data outside 
of the medical encounter, and may be leveraged to provide adherence and toxicity 
information to the healthcare team in real time.
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Objectives: Utility analyses have previously been conducted for the Phase III 
trial of vinflunine (VFL) versus best supportive care (BSC) for the treatment of 
advanced or metastatic transitional cell carcinoma of the urothelial tract (TCCU). 
Results were presented according to progression status. The present study aims 
to calculate quality-adjusted life years (QALYs) for each patient and summarise 
results by treatment group. MethOds: QALYs were calculated by patient using 
the area under the curve technique. Assumptions included that changes between 
utility measures over time were linear and utility at the time of death is zero. 
Once QALYs were calculated for all patients, univariate summaries were produced 
for both treatments separately considering different scenarios based on when 
baseline was recorded and how censored patients are handled in the QALY cal-
culation. The mean differences between treatments were evaluated using p-value 
derived from a two sample t-test and non-parametric Wilcoxon rank sum test. 
An analysis of covariance (ANCOVA), adjusting for baseline utility, was also per-
formed. Results: A total of 242 patients from the VFL and 103 from the BSC group 
had utility data and were eligible for the study. All BSC patients were observed to 
die, whilst 6% of VFL patients were censored and required imputation of death 
for QALY calculation. The estimated mean difference in QALY between treatment 
groups always favoured vinflunine regardless of method of analysis. Point esti-
mate ranged between -0.152 to -0.061. ANCOVA analyses move the point estimate 
slightly more in favour of vinflunine compared with unadjusted analyses. This 
was expected as the baseline utility was higher in the BSC group (0.781) compared 
to vinflunine (0.766). cOnclusiOns: Sensitivity analyses show that difference 
